

Keith E Stockerl-Goldstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5857697/publications.pdf>

Version: 2024-02-01

196
papers

10,754
citations

50276

46
h-index

33894

99
g-index

198
all docs

198
docs citations

198
times ranked

15171
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918. | 13.7 | 1,395 |
| 2 | Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101. | 16.8 | 847 |
| 3 | <i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036. | 27.0 | 663 |
| 4 | A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. <i>Blood</i> , 2012, 120, 1801-1809. | 1.4 | 393 |
| 5 | Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma—A Feasibility Study. <i>Blood</i> , 1999, 93, 2411-2419. | 1.4 | 385 |
| 6 | Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003, 102, 3447-3454. | 1.4 | 382 |
| 7 | A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2012, 119, 3917-3924. | 1.4 | 347 |
| 8 | Protective Conditioning for Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2005, 353, 1321-1331. | 27.0 | 319 |
| 9 | Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1045-1056. | 2.0 | 319 |
| 10 | Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. <i>Annals of Oncology</i> , 2021, 32, 787-800. | 1.2 | 240 |
| 11 | Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. <i>Blood</i> , 2004, 103, 777-783. | 1.4 | 192 |
| 12 | Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 230-269. | 4.9 | 166 |
| 13 | Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 262-271. | 2.0 | 152 |
| 14 | Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167. | 7.1 | 149 |
| 15 | Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1761-1769. | 2.0 | 143 |
| 16 | NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 11-20. | 4.9 | 142 |
| 17 | Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1685-1717. | 4.9 | 138 |
| 18 | Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 621-627. | 2.0 | 136 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. <i>Blood</i> , 2002, 99, 1442-1448. | 1.4 | 132 |
| 20 | Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 47-55. | 2.0 | 115 |
| 21 | Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 87-95. | 10.7 | 113 |
| 22 | NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1154-1165. | 4.9 | 113 |
| 23 | Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 908-942. | 4.9 | 112 |
| 24 | A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and S  zary Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 982-990. | 2.0 | 108 |
| 25 | Effect of Oral Glutamine Supplementation During Bone Marrow Transplantation. <i>Journal of Parenteral and Enteral Nutrition</i> , 2000, 24, 61-66. | 2.6 | 105 |
| 26 | A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. <i>Blood</i> , 2011, 117, 1828-1833. | 1.4 | 104 |
| 27 | Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience. <i>Journal of Clinical Oncology</i> , 2015, 33, 340-348. | 1.6 | 94 |
| 28 | Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1646-1652. | 2.0 | 92 |
| 29 | Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836. | 5.2 | 89 |
| 30 | Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: Results of a prospective double-blind randomized trial. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 254-261. | 2.0 | 86 |
| 31 | Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1854-1871. | 9.4 | 83 |
| 32 | Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for  International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 280-288. | 2.0 | 81 |
| 33 | High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 294-301. | 2.0 | 75 |
| 34 | Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. <i>Blood</i> , 2017, 129, 2680-2692. | 1.4 | 66 |
| 35 | Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 506-512. | 2.0 | 65 |
| 36 | Multiple Myeloma, Version 1.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 11-17. | 4.9 | 63 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 389-400. | 4.9 | 62 |
| 38 | Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biology of Blood and Marrow Transplantation, 1999, 5, 299-305. | 2.0 | 60 |
| 39 | Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1146-1183. | 4.9 | 58 |
| 40 | High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation, 2000, 6, 352-358. | 2.0 | 57 |
| 41 | Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood, 2005, 105, 2300-2306. | 1.4 | 57 |
| 42 | Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435. | 4.9 | 55 |
| 43 | Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma. American Journal of Health-System Pharmacy, 2015, 72, 353-360. | 1.0 | 52 |
| 44 | A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. American Journal of Hematology, 2009, 84, 560-564. | 4.1 | 51 |
| 45 | Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. Diabetes, 2015, 64, 2969-2977. | 0.6 | 50 |
| 46 | Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Science Translational Medicine, 2022, 14, eabm1375. | 12.4 | 49 |
| 47 | Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer, 2017, 123, 2025-2034. | 4.1 | 48 |
| 48 | Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 2000, 6, 387-394. | 2.0 | 47 |
| 49 | Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leukemia and Lymphoma, 2015, 56, 2643-2649. | 1.3 | 47 |
| 50 | Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. Biology of Blood and Marrow Transplantation, 2012, 18, 125-133. | 2.0 | 46 |
| 51 | Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. Cancer, 2018, 124, 816-825. | 4.1 | 44 |
| 52 | CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Experimental Hematology, 2005, 33, 279-285. | 0.4 | 43 |
| 53 | Multiple Myeloma Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 118. | 4.9 | 43 |
| 54 | Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. JAMA Network Open, 2022, 5, e224304. | 5.9 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. American Journal of Hematology, 2009, 84, 733-737. | 4.1 | 42 |
| 56 | Geriatric Assessment in Older Adults with Multiple Myeloma. Journal of the American Geriatrics Society, 2019, 67, 987-991. | 2.6 | 42 |
| 57 | A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer Journal, 2017, 7, e542-e542. | 6.2 | 41 |
| 58 | Cardio-Oncology Education and Training. Journal of the American College of Cardiology, 2020, 76, 2267-2281. | 2.8 | 41 |
| 59 | Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood, 2022, 139, 1177-1183. | 1.4 | 41 |
| 60 | Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study. American Journal of Hematology, 2011, 86, 796-800. | 4.1 | 39 |
| 61 | Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica, 2014, 99, e162-e164. | 3.5 | 39 |
| 62 | Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1072-1077. | 2.0 | 39 |
| 63 | Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1211-1219. | 4.9 | 38 |
| 64 | A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia, 2013, 27, 725-728. | 7.2 | 38 |
| 65 | Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis. JACC Basic To Translational Science, 2019, 4, 438-448. | 4.1 | 38 |
| 66 | Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma. Oncologist, 2013, 18, 1074-1079. | 3.7 | 36 |
| 67 | High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Bone Marrow Transplantation, 2015, 50, 1075-1082. | 2.4 | 36 |
| 68 | Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. British Journal of Haematology, 2020, 188, 501-510. | 2.5 | 36 |
| 69 | Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biology of Blood and Marrow Transplantation, 2001, 7, 552-560. | 2.0 | 35 |
| 70 | Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2016, 128, 2142-2142. | 1.4 | 34 |
| 71 | Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. International Journal of Hematology, 2014, 99, 272-278. | 1.6 | 32 |
| 72 | Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology, 2018, 180, 821-830. | 2.5 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-------|-----------|
| 73 | DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2020, 38, 8502-8502. | 1.6 | 32 |
| 74 | Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 2021, 4, e2134330. | 5.9 | 32 |
| 75 | Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leukemia Research, 2016, 49, 1-6. | 0.8 | 31 |
| 76 | Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. British Journal of Haematology, 2018, 182, 495-503. | 2.5 | 30 |
| 77 | Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer, 2018, 124, 4342-4349. | 4.1 | 29 |
| 78 | Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-oncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504. | 329.8 | 29 |
| 79 | Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347. | 7.2 | 27 |
| 80 | DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 19-20. | 1.4 | 27 |
| 81 | Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. Bone Marrow Transplantation, 2009, 43, 793-800. | 2.4 | 26 |
| 82 | A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766. | 16.8 | 26 |
| 83 | A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 2100-2105. | 2.0 | 25 |
| 84 | Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression. Blood, 2012, 120, 331-331. | 1.4 | 24 |
| 85 | Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status. Blood, 2014, 124, 555-555. | 1.4 | 24 |
| 86 | Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transplant Infectious Disease, 2012, 14, 259-267. | 1.7 | 23 |
| 87 | Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 140-140. | 1.4 | 22 |
| 88 | Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Cancer Medicine, 2017, 6, 2814-2821. | 2.8 | 21 |
| 89 | Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. Transplantation and Cellular Therapy, 2022, 28, 510.e1-510.e9. | 1.2 | 20 |
| 90 | Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplantation, 2009, 44, 13-17. | 2.4 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. American Journal of Hematology, 2015, 90, 1106-1110. | 4.1 | 19 |
| 92 | Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 2065-2069. | 2.0 | 19 |
| 93 | GENESIS: Phase III trial evaluating BL-8040+ÂG-CSF to mobilize hematopoietic cells for autologous transplant in myeloma. Future Oncology, 2019, 15, 3555-3563. | 2.4 | 18 |
| 94 | Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 285-289. | 0.4 | 17 |
| 95 | Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica, 2020, 105, e404-e407. | 3.5 | 16 |
| 96 | A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. American Journal of Hematology, 2014, 89, E103-8. | 4.1 | 15 |
| 97 | Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation, 2000, 6, 555-562. | 2.0 | 14 |
| 98 | Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 1153-1154. | 2.0 | 14 |
| 99 | A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 728-730. | 1.3 | 14 |
| 100 | A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2019, 25, 3776-3783. | 7.0 | 14 |
| 101 | High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: Experience in California. Biology of Blood and Marrow Transplantation, 2000, 6, 496-505. | 2.0 | 13 |
| 102 | High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2006, 12, 703-711. | 2.0 | 13 |
| 103 | Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy. Biology of Blood and Marrow Transplantation, 2000, 6, 58-69. | 2.0 | 12 |
| 104 | The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leukemia and Lymphoma, 2014, 55, 337-341. | 1.3 | 12 |
| 105 | Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 1425-1430. | 2.0 | 12 |
| 106 | DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Annals of Hematology, 2020, 99, 1041-1048. | 1.8 | 12 |
| 107 | Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discovery, 2022, 3, 181-193. | 5.0 | 12 |
| 108 | A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. Leukemia and Lymphoma, 2016, 57, 2535-2540. | 1.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. <i>Blood Advances</i> , 2022, 6, 1991-2000. | 5.2 | 11 |
| 110 | Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , 2014, 124, 31-31. | 1.4 | 11 |
| 111 | Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2012, 47, 516-521. | 2.4 | 10 |
| 112 | Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML.. <i>Blood</i> , 2010, 116, 1060-1060. | 1.4 | 10 |
| 113 | Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 487-492. | 4.1 | 9 |
| 114 | Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046. | 5.9 | 9 |
| 115 | Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies. <i>Cancer</i> , 2001, 91, 2205-2213. | 4.1 | 8 |
| 116 | Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2155-2158. | 2.0 | 8 |
| 117 | Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.. <i>Blood</i> , 2008, 112, 1944-1944. | 1.4 | 8 |
| 118 | Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. <i>Transfusion</i> , 2016, 56, 2331-2335. | 1.6 | 7 |
| 119 | Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy. <i>Pharmacotherapy</i> , 2016, 36, 1087-1094. | 2.6 | 7 |
| 120 | Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. <i>Leukemia Research</i> , 2018, 72, 86-91. | 0.8 | 7 |
| 121 | Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. <i>Blood</i> , 2017, 130, 816-816. | 1.4 | 7 |
| 122 | COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments. <i>Acta Haematologica</i> , 2022, 145, 244-256. | 1.4 | 7 |
| 123 | Retrospective comparison of allogeneic vs autologous transplantation for diffuse large B-cell lymphoma with early relapse or primary induction failure. <i>Bone Marrow Transplantation</i> , 2015, 50, 134-136. | 2.4 | 6 |
| 124 | A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e588-e593. | 0.4 | 6 |
| 125 | Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 631-631. | 1.4 | 6 |
| 126 | A Retrospective Review of Response to Donor Leukocyte Infusions In Adults with Acute Myeloid Leukemia After Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation.. <i>Blood</i> , 2010, 116, 4512-4512. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1282-1289. | 2.0 | 5 |
| 128 | Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 687-693. | 2.0 | 5 |
| 129 | Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis. <i>Blood</i> , 2020, 136, 28-30. | 1.4 | 5 |
| 130 | A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML. <i>Blood</i> , 2009, 114, 787-787. | 1.4 | 5 |
| 131 | Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. <i>Blood</i> , 2010, 116, 862-862. | 1.4 | 5 |
| 132 | COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury. <i>American Journal of Medicine</i> , 2022, 135, S49-S52. | 1.5 | 5 |
| 133 | Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e363-e364. | 0.4 | 4 |
| 134 | A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy. <i>American Heart Journal</i> , 2021, 232, 137-145. | 2.7 | 4 |
| 135 | Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. <i>JCO Precision Oncology</i> , 2021, 5, 191-203. | 3.0 | 4 |
| 136 | A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. <i>Blood</i> , 2014, 124, 1931-1931. | 1.4 | 4 |
| 137 | A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 276-282. | 2.0 | 3 |
| 138 | A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , 2013, 122, 5492-5492. | 1.4 | 3 |
| 139 | A Randomized Trial of Tbo-Filgrastim Versus Filgrastim for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 516-516. | 1.4 | 3 |
| 140 | How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis. <i>JACC: CardioOncology</i> , 2021, 3, 590-593. | 4.0 | 3 |
| 141 | A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, 62, 1441-1449. | 1.3 | 2 |
| 142 | Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. <i>Bone Marrow Transplantation</i> , 2021, 56, 2016-2018. | 2.4 | 2 |
| 143 | Geriatric Assessment in Older Adults with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 1286-1286. | 1.4 | 2 |
| 144 | The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant. <i>Blood</i> , 2016, 128, 3563-3563. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety. Blood, 2016, 128, 4497-4497. | 1.4 | 2 |
| 146 | Financial Toxicity Among Patients with Multiple Myeloma. Blood, 2021, 138, 4027-4027. | 1.4 | 2 |
| 147 | An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Therapeutic Advances in Hematology, 2022, 13, 204062072210884. | 2.5 | 2 |
| 148 | A decade of progress in allogeneic hematopoietic cell transplantation: 1990â€“2000. Advances in Cancer Research, 2001, 81, 1-59. | 5.0 | 1 |
| 149 | Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1188-1190. | 2.4 | 1 |
| 150 | The effect of donor type on outcomes in adults with acute myeloid leukemia after reducedâ€“intensity hematopoietic peripheral blood cell transplant â€“ a retrospective study. Transplant International, 2020, 33, 1089-1098. | 1.6 | 1 |
| 151 | A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 3043-3046. | 1.3 | 1 |
| 152 | Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study. Blood, 2018, 132, 5666-5666. | 1.4 | 1 |
| 153 | Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. Blood, 2009, 114, 3417-3417. | 1.4 | 1 |
| 154 | Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection.. Blood, 2010, 116, 1063-1063. | 1.4 | 1 |
| 155 | Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection. Blood, 2010, 116, 823-823. | 1.4 | 1 |
| 156 | Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.. Blood, 2012, 120, 2965-2965. | 1.4 | 1 |
| 157 | Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 2557-2557. | 1.4 | 1 |
| 158 | CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2015, 126, 3098-3098. | 1.4 | 1 |
| 159 | Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689. | 1.4 | 1 |
| 160 | Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience. Blood, 2016, 128, 5611-5611. | 1.4 | 1 |
| 161 | A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia,. Blood, 2011, 118, 3616-3616. | 1.4 | 1 |
| 162 | Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 2456-2456. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma. Blood, 2018, 132, 2021-2021. | 1.4 | 1 |
| 164 | Disparities in Healthcare Resource Utilization for Multiple Myeloma. Blood, 2018, 132, 4793-4793. | 1.4 | 1 |
| 165 | Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma. Blood, 2018, 132, 5627-5627. | 1.4 | 1 |
| 166 | The Irf of IRE1Î±: Overexpression of IRE1Î± at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1Î± Expression Is Predictive of Therapy Resistance. Blood, 2019, 134, 4351-4351. | 1.4 | 1 |
| 167 | Commentary. Clinical Chemistry, 2012, 58, 675-675. | 3.2 | 0 |
| 168 | A phase I study of thymoglobulin for relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2016, 57, 453-455. | 1.3 | 0 |
| 169 | The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation. Leukemia and Lymphoma, 2017, 58, 241-243. | 1.3 | 0 |
| 170 | Busulfan/Fludarabine/Thymoglobulin as a Reduced Intensity Conditioning Regimen for Lymphoid Malignancies.. Blood, 2009, 114, 3335-3335. | 1.4 | 0 |
| 171 | Outcomes In Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: A Single Center's 12-Year Experience. Blood, 2010, 116, 2360-2360. | 1.4 | 0 |
| 172 | Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. Blood, 2010, 116, 680-680. | 1.4 | 0 |
| 173 | Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia,. Blood, 2011, 118, 3633-3633. | 1.4 | 0 |
| 174 | Genomic Landscape of Immunoglobulin Light Chain (AL) Amyloidosis and Comparative Analyses with Related Malignant Plasma Cell Disorder- Multiple Myeloma. Blood, 2011, 118, 809-809. | 1.4 | 0 |
| 175 | Phase I Study of Cladribine (2-chlorodeoxyadenosine), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML,. Blood, 2011, 118, 3609-3609. | 1.4 | 0 |
| 176 | High Throughput Digital Quantification of Genomic Copy Number Alterations in Multiple Myeloma. Blood, 2011, 118, 1830-1830. | 1.4 | 0 |
| 177 | Genome-Wide Copy Number Analyses Correlated with Outcomes in Untreated Multiple Myeloma Patients. Blood, 2012, 120, 3991-3991. | 1.4 | 0 |
| 178 | A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. Blood, 2013, 122, 3931-3931. | 1.4 | 0 |
| 179 | Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. Blood, 2013, 122, 2816-2816. | 1.4 | 0 |
| 180 | Front-Line Radiotherapy Is Associated with Shortened Survival in Newly Diagnosed Multiple Myeloma Patients. Blood, 2014, 124, 5696-5696. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Impact of Remission Status on Outcomes in AML Patients ≥ 60 Years of Age after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1263-1263. | 1.4 | 0 |
| 182 | A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. Blood, 2014, 124, 5292-5292. | 1.4 | 0 |
| 183 | A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma. Blood, 2014, 124, 4731-4731. | 1.4 | 0 |
| 184 | Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 850-850. | 1.4 | 0 |
| 185 | Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 3144-3144. | 1.4 | 0 |
| 186 | Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 1853-1853. | 1.4 | 0 |
| 187 | Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Blood, 2015, 126, 3196-3196. | 1.4 | 0 |
| 188 | Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2016, 128, 2133-2133. | 1.4 | 0 |
| 189 | Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma. Blood, 2016, 128, 2349-2349. | 1.4 | 0 |
| 190 | The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma. Blood, 2018, 132, 4463-4463. | 1.4 | 0 |
| 191 | A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Blood, 2018, 132, 2146-2146. | 1.4 | 0 |
| 192 | The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients. Blood, 2018, 132, 3439-3439. | 1.4 | 0 |
| 193 | Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5701-5701. | 1.4 | 0 |
| 194 | Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial. Blood, 2021, 138, 2849-2849. | 1.4 | 0 |
| 195 | A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma. Blood, 2020, 136, 31-32. | 1.4 | 0 |
| 196 | What Do The Elevated Protein Levels Mean In My Patients With Myeloma, Amyloidosis, and Related Disorders?. American Journal of Medicine, 2022, , . | 1.5 | 0 |